CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases

被引：6

作者：

Chevalier, Kevin ^{[1
]}

Genin, Michael ^{[2
]}

Jean, Thomas Petit ^{[3
]}

Avouac, Jerome ^{[4
]}

Flipo, Rene-Marc ^{[5
]}

Georgin-Lavialle, Sophie ^{[6
]}

El Mahou, Soumaya ^{[7
]}

Pertuiset, Edouard ^{[8
]}

Pham, Thao ^{[9
]}

Servettaz, Amelie ^{[10
]}

Marotte, Hubert ^{[11
]}

Domont, Fanny ^{[12
]}

Chazerain, Pascal ^{[13
]}

Devaux, Mathilde ^{[14
]}

Mekinian, Arsene ^{[15
]}

Sellam, Jeremie ^{[16
]}

Fautrel, Bruno ^{[17
]}

Rouzaud, Diane ^{[18
]}

Ebstein, Esther ^{[19
]}

Costedoat-Chalumeau, Nathalie ^{[20
]}

Richez, Christophe ^{[21
]}

Hachulla, Eric ^{[22
]}

Mariette, Xavier ^{[1
]}

Seror, Raphaele ^{[1
]}

机构：

[1] Univ Paris Saclay, Hop Bicetre, Ctr Immunol Viral Infect & Autoimmune Dis, INSERM,UMR 1184,Dept Rheumatol,AP HP, Le Kremlin Bicetre, France

[2] Univ Lille, CHU Lille, ULR METRICS Evaluat Technol St & Prat Med 2694, Lille, France

[3] AP HP, Dept Innovat & Donnees, Paris, France

[4] Cochin Hosp, Rheumatol A, Paris, France

[5] Univ Lille, Rheumatol, Lille, France

[6] Tenon Hosp, Internal Med, Paris, France

[7] Hosp Ctr Tourcoing, Rheumatol, Tourcoing, France

[8] Hosp Rene Dubos, Rheumatol, Pontoise, France

[9] Hosp St Marguer, Rheumatol, Marseille, France

[10] Hosp Robert Debre, Internal Med, Infect Dis & Clin Immunol, Reims, France

[11] Univ Hosp St Etienne, Rheumatol, St Priest En Jarez, France

[12] Univ Hosp Pitie Salpetriere Charles Foix, Internal Med & Clin Immunol, Paris, France

[13] Hop Croix St Simon, Rheumatol & Internal Med, Paris, France

[14] St Germain En Laye Intercommunal Hosp Ctr, Internal Med, Poissy, France

[15] Hosp St Antoine, AP HP, Internal Med, Paris, France

[16] Hosp St Antoine, AP HP, Rheumatol, Paris, France

[17] Sorbonne Univ, Pitie Salpetriere Hosp, Pierre Louis Inst Epidemiol & Publ Hlth, Dept Rheumatol,AP HP,INSERM,UMRS 1136, Paris, France

[18] Bichat Claude Bernard Hosp, Internal Med, Paris, France

[19] Bichat Claude Bernard Hosp, Rheumatol, Paris, France

[20] Cochin Hosp, Internal Med, Paris, France

[21] Chu Bordeaux Site Pellegrin, Rheumatol, Bordeaux, France

[22] Univ Lille, Inst Translat Res Inflammat, Referral Ctr Ctr Rare Syst Autoimmune Dis North &, Dept Internal Med & Clin Immunol,CHU Lille,INSERM,, Lille, France

来源：

FRONTIERS IN MEDICINE | 2023年 / 10卷

关键词：

COVID-19; auto-immune diseases; inflammatory rheumatic diseases; rituximab; lupus; vasculitis; rheumatic and musculoskeletal diseases; CLINICAL CHARACTERISTICS; HOSPITALIZED-PATIENTS; OUTCOMES; PNEUMONIA; THERAPY;

D O I：

10.3389/fmed.2023.1152587

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionAutoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death. Materials and methodsTwo databases were analyzed: the EDS (Entrepot des Donnees de Sante, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls. ResultsAmong 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)]. ConclusionIn this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.

引用

页数：15

共 50 条

[31] Factors Associated with Mortality Among Severe Omicron Patients for COVID-19
Wu, Shuting
Liao, Guichan
Mao, Jingchun
Yan, Haiming
Chen, Juanjuan
Peng, Jie
INFECTION AND DRUG RESISTANCE, 2024, 17 : 1309 - 1319
[32] Persistent Risk of Developing Autoimmune Diseases Associated With COVID-19
Inokuchi, Shoichiro
Shimamoto, Koji
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (02) : 65 - 72
[33] Impact of COVID-19 pandemic on management of autoimmune and inflammatory diseases in Morocco
Wafa, Ammouri
Hicham, Harmouche
Hajar, Khibri
Mouna, Maamar
Zoubida, Mezalek Tazi
Mohamed, Adnaoui
PAN AFRICAN MEDICAL JOURNAL, 2020, 37
[34] Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases
Sher, Emina Karahmet
Cosovic, Adnan
Dzidic-Krivic, Amina
Farhat, Esma Karahmet
Pinjic, Emma
Sher, Farooq
LIFE SCIENCES, 2023, 319
[35] POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY
Gupta, Latika
Sen, Parikshit
Naveen, R.
Joshi, Mrudula
Saha, Sreoshy
Jagtap, Kshitij
Agarwal, Vishwesh
Distler, Oliver
Nikiphorou, Elena
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Milchert, Marcin
Parodis, Ioannis
Kuwana, Masataka
Makol, Ashima
Pauling, John D.
Wincup, Chris
Lilleker, James
Nune, Arvind
Day, Jessica
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
RHEUMATOLOGY, 2023, 62
[36] Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Schulze-Koops, Hendrik
Krueger, Klaus
Vallbracht, Inka
Hasseli, Rebecca
Skapenko, Alla
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05)
[37] IMPACT OF THE COVID-19 PANDEMIC ON CHRONIC INFLAMMATORY RHEUMATISM
El Mabrouk, Y.
Fazaa, A.
Miladi, S.
Ouenniche, K.
Sallemi, M.
Souebni, L.
Kassab, S.
Chekili, S.
Ben Abdelghani, K.
Laatar, A.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S377 - S377
[38] Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
Yap, Ruth Xian Lynn
Lai, Yi Wye
Wei, Chang
Ng, Joel Jia Wei
Xu, Dan
Feng, Shuo
Mu, Rong
Thong, Bernard Yu-Hor
Xu, Chuanhui
VACCINES, 2024, 12 (03)
[39] RISK FACTORS FOR SEVERE COVID-19 INFECTION AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIRD) AND THE IMPACT OF VACCINATIONS - AN ISRAELI, MULTI-CENTER EXPERIENCE
Kharouf, F.
Eviatar, T.
Braun, M.
Pokroy-Shapira, E.
Brodavka, M.
Agmon-Levin, N.
Toledano, K.
Oren, S.
Lidar, M.
Vazina, M. Amit
Sabbah, F.
Tavor, Y.
Breuer, G.
Zisman, D.
Markovits, D.
Dagan, A.
Garzuzi, R. Bishara
Shifman, O.
Giryes, S.
Elias, M.
Feld, J.
Reitblat, T.
Gazit, T.
Hadad, A.
Elkayam, O.
Paran, D.
Mevorach, D.
Balbir-Gurman, A.
Braun-Moscovici, Y.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 962 - 962
[40] IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH ICU ADMISSION IN COVID-19 PATIENTS
Kukreja, I
Chopra, A.
Arora, A.
Verma, V.
Shukla, A.
VALUE IN HEALTH, 2022, 25 (01) : S258 - S258

← 1 2 3 4 5 →